Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 14, Issue 11, Pages 1445-1453Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/17512433.2021.1964953
Keywords
Thalassemia; iron-chelators; iron overload; silymarin; legalon; milk thistle
Categories
Ask authors/readers for more resources
The combination therapy of silymarin and iron chelators in transfusion-dependent beta-thalassemia patients can significantly improve serum ferritin levels, but does not have a significant effect on reducing liver iron concentration.
Background and aim: We conducted a systematic review to apprise the efficacy of silymarin in conjunction with standard iron chelators on iron overload for transfusion-dependent beta-thalassemia (TDT) patients. Methods: We searched PubMed, Web of Science, Scopus, Sciencedirect, the Cochrane Library (the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials (CENTRAL) to 1 May 2020. All randomized controlled trials (RCTs) studies comparing the effect of iron chelators alone versus silymarin plus standard routine treatment on iron burden amid TDT were included in this review. Primary outcomes comprised serum ferritin level (ng/mL), liver iron concentration (LIC Fe/kg dry weight), and total iron binding capacity (TIBC mcg/dL) Results: Combination therapy of silymarin and iron chelators showed a significant improvement in serum ferritin level in TDT patients, compared to nonsilymarin users [eight studies, n = 477]; weighted mean difference (WMD) -1.79, 95% confidence interval [CI] -2.86 to -0.72, I-2 96.1%; P = 0.001. Concurrent treatment with silymarin failed to significantly decrease LIC in TDT patients [two studies, n = 106]; WMD 0.74, 95% CI -1.62 to 3.10, I-2 96.6%; P = 0.54. Conclusion: There is no evidence of the effectiveness of adding silymarin to standard iron chelators to reduce iron load in TDT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available